year left
short interest float
aileron alrn clinical-stag biotechnolog compani
develop stapl peptid treatment solid liquid tumor stapl peptid
novel therapeut drug class design mimic biolog activ conform specif
target inhibit protein-protein interact aileron lead candid target
factor involv regul tumor suppress function cancer
shown favor safeti profil sign clinic efficaci solid liquid tumor
compani current sponsor separ clinic studi phase i/ii studi
expans cohort patient relaps refractori peripher cell
lymphoma r/r phase i/ib trial drug elderli patient advanc
acut myeloid leukemia aml myelodysplast syndrom md compani expect
provid updat studi
point discuss
aileron develop first-in-class novel therapi reactiv stapl
peptid novel therapeut class drug design provid enhanc bind
toward target protein compar convent small molecul inhibitor
compani lead product intraven deliv stapl peptid inhibitor
mdmx neg regul function therapi
optim hydrocarbon stapl a-hel peptid mimic a-hel conform
found essenti bait mdmx allow elicit
tumor suppressor activitycel cycl arrest apoptosi malign cell
differenti inhibitor develop prevent activ
mdmx shown requir effect reactiv
mdmx overexpress associ poor clinic outcom
mdmx act neg regul overexpress either protein
shown oncogen potenti inde protein overexpress mdmx
occur variou cancer type includ sarcoma melanoma breast cancer sever
blood cancer estim acut myeloid leukemia aml case
overexpress mdmx mani retain wild-typ highlight potenti
mean interrupt interact restor
function aileron current sponsor phase ib studi singl
agent combin cytarabin patient acut myeloid leukemia aml
myelodysplast syndrom md expect report data
interim data phase i/ii studi
updat phase i/ib studi aml/md
report preclin data evalu combin
initi clinic studi evalu combin solid
analyst certif disclosur pleas see page
shown sign clinic activ liquid solid tumor aileron report data
phase dose escal all-com studi patient across differ advanc solid tumor
lymphoma drug well toler complet respons cr merkel cell carcinoma
peripher cell lymphoma data subject expans cohort patient relapsed/refractori
r/r show overal respons rate orr diseas control rate dcr use lugano
criteria orr dcr use cheson et al criteria data approach case
exceed orr report approv therapi r/r howev note data small
number patient would need follow patient order better understand
therapeut benefit popul aileron expect give updat regard studi
also shown sign clinic activ elderli patient relaps refractori aml advanc
md indic high unmet medic need compani report data patient treat alrn-
experienc reduct bone marrow blast well marrow md patient treat
plu cytarabin compani recent report patient death result tumor lysi syndrom
tl attribut increas activ result aileron implement prophylact
measur curtail tl
unmet need toler durabl treatment r/r patient recurr diseas bleak
prognosi given absenc effect treatment strategi median overal surviv mo r/r
patient elig autolog stem cell transplant asct induct therapi month
month respect salvag chemotherapi margin improv outcom patient mo
month month respect current fda approv therapi treatment
r/r howev durat respons toler major limit emphas unmet medic need
patient far shown respons rate in-lin approv therapi although
encourag await data regard respons durabl larger data set improv
understand drug potenti indic
term safeti common clinic relev laboratori seen first-in-human phase studi
grade lymphocyt count decreas grade case grade hyponatremia neutropenia
thrombocytopenia promin seen approv candid therapi develop
respect compar favor neutropenia
thrombocytopenia approv agent view data posit like see data patient
treat gaug potenti safeti benefit
preclin studi provid basi ration combin strategi play essenti role
suppress tumor develop estim roughli human cancer harbor mutat delet
render non-funct remain cancer wild type level tightli regul
mdmx overexpress either factor potenti oncogen given
promin role tumor develop unforeseen regul function may form part
mechan action mani anti-canc regimen aileron shown posit preclin data
combin inhibitor paclitaxel blockad select solid tumor type believ
studi bode well aileron given increas appetit larg pharma potenti combinatori therapeut
approach inhibitor billion-dollar therapeut class expect grow
futur potenti partnership player space mayb futur sourc capit aileron
second quarter financi second quarter aileron report research develop cost
million compar million period gener administr cost million
compar million second quarter compani report net loss million
per share compar net loss million per share prior convers proffer stock
period june aileron cash cash equival invest
million includ million cash
tabl content
stapl peptid dual inhibitor mdmx treatment wild type cancer
durat respons toler repres area unmet medic need patient receiv
treatment relapsed/refractori peripher cell lymphoma r/r
poor median overal surviv r/r aml md emphas need new therapi
aml market
shown sign efficaci r/r r/r aml advanc md
on-going phase iia expans cohort studi
on-going phase i/ib trial r/r aml advanc md
competit landscap achiev high orr increas durabl demonstr
favor safeti profil success
differenti approach reactiv show promis safeti efficaci
risk invest
aileron clinic stage compani develop stapled-peptid therapi treatment solid
liquid tumor stapl peptid novel therapeut class therapi design provid enhanc bind toward
target protein compar convent small molecul inhibitor compani lead product
intraven deliv stapl peptid inhibitor mdmx neg regul function
shown abil stabil reactiv tumor suppress function inhibit
mdmx may point differenti compar inhibitor develop
treatment overal well-toler shown evid anti-tumor activ peripher cell lymphoma
acut myeloid leukemia aml myelodysplast syndrom md solid tumor aileron
current sponsor separ studi evalu treatment hematolog malign
larg unmet medic need first phase i/ii trial patient relaps refractori r/r
harbor wild type second phase i/ib studi singl agent combin
cytarabin patient r/r aml md wild type aileron expect report interim find
expans cohort well data singl agent combin arm aml/md studi
compani shown posit preclin data combin
inhibitor paclitaxel blockad select solid tumor aileron development pipelin present
figur aileron also plan investig led trial begin soon test solid liquid pediatr
stapl peptid dual inhibitor mdmx treatment wild
canon suppressor prolifer
gene encod transcript factor protein known respond varieti cellular stress
regul express target gene order induc cell cycl arrest apoptosi cellular senesc dna
repair alter metabol normal cell protein level low regul part ubiquitin
pathway context tag ubiquitin subsequ degrad proteasom level
increas dna damag cellular stress signal detect lead accumul
nucleu transcript gene associ dna repair growth arrest apoptosi way abl
control cell cycl avoid prolifer abnorm cell apoptosi gene function
inactiv loss function alter abnorm sometim cancer cell left uncheck prolifer
uncontrol
mdmx regul function
spatial tempor level within cell critic function shown figur main
regul ubiquitin-protein ligas homolog mdmx ring finger protein
bind protein shown interact play distinct nonoverlap role
regul contain nuclear import export signal allow shuttl activ
nucleu cytosol ubiquitin turn facilit degrad via proteasom
activ also regul activ bind transactiv domain inhibit
transcript activ express regul therefor level correl
stabil phosphoryl serin posit threonin posit serin
posit disrupt normal cell neither residu phosphoryl
therefor maintain low level howev dna damag detect phosphoryl one
residu releas avoid downregul level also rise context
virtu activ howev neg regulatori activ preclud given
phosphoryl dna damag clear dephosphoryl allow elimin excess
bouchet et al target anti-canc drug develop critic oncol hematol
eishen et al role mdmx dna repair mol cell biol feb
urso et al critic review cancer possibl role malign mesothelioma implic
treatment critic review oncology/hematolog
 et al modul interact phosphoryl comput studi cell
figur regul mdmx
aileron corpor present modifi lifesci capit
mdmx shown play two distinct role regul first interact
transactiv domain order limit transcript activ target gene mdmx also regul
function stabil thu enhanc abil ubiquitin destruct
convers neg regul mdmx requir function cell detect dna damag mdmx
quickli degrad augment activ
recent evid point model effect inhibit function brought
mdmx act complex complex shown requir optim ligas activ
reciproc manner mdmx mediat regul depend abil escort activ
nucleu cytoplasm complex essenti regul function given
genet disrupt ring domain result mark activ
mdmx overexpress cancer
mdmx protein act neg regul therefor surpris either protein
left uncheck becom oncogen preclin model separ overexpress mdmx
result tumor format although tumorigen abil mdmx shown context depend one
vivo studi overexpress acceler onset tumor format null anim
suggest oncogen activ mediat inhibit function protein
overexpress mdmx occur variou cancer type includ sarcoma melanoma breast cancer
sever blood cancer major maintain wild-typ function estim
acut myeloid leukemia aml case overexpress mdmx mani retain wild-typ data highlight
shadfan et al mdmx alon togeth regul tran
han et al high express human homologu murin doubl minut short splice variant
bone marrow patient acut myeloid leukemia myelodysplast syndrom clin lymphoma myeloma leuk
neg regulatori role mdmx point potenti disrupt
interact mean restor alerion believ interrupt
interact mdmx restor function result pro-apoptot anti-tumor activ
current evalu phase studi solid tumor lymphoma demonstr favor
safeti profil sign anti-canc activ compound also assess phase i/ib studi
relapsed/refractori aml advanc myelodysplast syndrom md
bait mdmx restor function
aileron lead candid optim hydrocarbon stapl a-hel peptid mimic a-hel
conform found result dual inhibit mdmx subsequ reactiv
mention earlier overexpress mdmx neg regul function result
uncheck prolifer cancer cell intraven therapi design induc cell cycl arrest
apoptosi insid cell act decoy mimic directli bind mdmx
turn reliev sequestr subsequ abl elicit tumor suppressor activ via activ
transcript target shown figur reactiv function result cell cycl arrest
apoptosi malign cell
figur mechan action cancer cell
onel cordon-cardo prognosi mol
urso et al critic review cancer possibl role malign mesothelioma implic
treatment critic review oncology/hematolog
evalu vitro vivo preclin studi vitro studi confirm drug
specif biochem properti ensur work wild type cancer line
higher bind affin mdmx endogen protein vivo studi investig
activ model includ breast cancer variou lymphoma acut myeloid leukemia result
preclin studi promot analysi function clinic trial all-com
trial drug test broader rang indic current investig
aml patient
specif wild type cancer line order investig activ
wild type mutant cancer line aileron perform cell prolifer assay across cancer cell line
harbor either wild type mutat data present figur drug effect
cell line mutant blue contrast cell line wild type sensit
sub micromolar concentr grey unaffect wild type cancer cell line hpv-
driven cancer cell expect given hpv protein abl destroy
figur vitro studi cell line
suppress tumor growth breast cancer model order evalu antitumor potenti
solid tumor model breast cancer mice treat twice week vari dose alrn-
vehicl day period figur show signific dose depend anti-prolif activ alrn-
compar vehicl treat control mice dose rang
figur result vivo studi breast cancer model
show potent anti-cancer activ across differ pdx model compar standard
antitumor effect evalu across patient-deriv xenograft pdx model
lymphoma harbor wild type compar celgen celg istodax romidepsin histon
deacetylas inhibitor hdac approv treatment cutan peripher cell lymphoma ctcl
shown figur red significantli reduc tumor burden compar vehicl black
romidepsin blue treat anim
figur result vivo studi romidepsin lymphoma
improv surviv aml model compar cyclophosphamid studi mice
receiv human aml xenograft subsequ treat biweekli mg/kg week
compar control mice treat shown figur median overal surviv mo mice
treat roughli day compar day control mice
evalu vari dose schedul efficaci system mv human leukemia xenograft
model charl river studi
figur result vivo studi cyclophosphamid aml patient
found gener well toler phase studi patient receiv mg/kg
week mg/kg twice week frequent report treatment relat grade advers event nausea
fatigu vomit anemia common side effect cancer therapi
manag medic studi report case seriou advers grade hypotens potenti risk
drug attribut side effect infus term clinic relev laboratori abnorm
common grade ae decreas lymphocyt count hyponatremia aileron recent
report death patient treat dose escal portion phase i/ib studi r/r
aml md patient die tumor lysi syndrom tl infus mg/kg
studi continu enrol patient treat mg/kg per
durat respons toler repres area unmet medic need
patient receiv treatment relapsed/refractori peripher cell lymphoma r/r
background peripher cell lymphoma ptcl group non-hodgkin lymphoma nhl includ
extens rang sub-ent poor clinic outcom although patient gener
experi favor respons rate chemotherapi remiss often short-liv result patient
malign often relaps case refractori diseas salvag chemotherapi without
consolid shown produc long-term remiss relapsed/refractori r/r
poor outcom poor surviv current fda approv therapi treatment r/r
howev durat respons toler major limit therapi emphas unmet
medic need patient aileron complet open-label dose escal all-com phase ib studi
patient across differ advanc solid tumor lymphoma show complet respons
cr patient toler grade associ neutropenia compani
current sponsor phase iia studi r/r
ptcl heterogen group nhl non-hodgkin lymphoma common form lymphoma
affect cell cell diseas begin lymphocyt form white blood cell
lymphat system often present organ outsid lymph node time diagnosi roughli
nhl case occur b-cell affect t-cell approxim new case nhl
diagnos estim peopl die diseas us ptcl divers group
cell lymphoma distinct subtyp malign gener categor main subtyp ptcl
otherwis specifi ptcl-no angioimmunoblast cell lymphoma aitl anaplast larg cell
lymphoma alcl anaplast lymphoma kinas posit alcl neg alcl
diagnosi usual difficult due larg part overlap subtyp although recent progress
molecular genet character diseas help identifi differ similar
numer subtyp turn help inform novel treatment diagnosi confirm usual
examin lymph node biopsi patient evalu base age stage diseas assign
one follow treatment cours
induct therapi exampl common regimen includ cyclophosphamid doxorubicin
vincristin prednison chop chop etoposid echop treatment induc high
respons rate depend histolog patient group complet respons rate patient
receiv chop rang howev year overal surviv treat patient
consolid therapi standard regimen includ hematopoiet cell transplant hct
radiat therapi autolog stem cell transplant asct indic patient fail
convent chemotherapi except alcl local
year overal surviv os patient receiv acst howev patient
unabl receiv acst due earli evalu first line set acst
demonstr cr rate year os diseas free surviv set
relaps set patient recurr diseas bleak prognosi repres area larg
unmet medic need given lack effect treatment strategi mention earlier larg
number patient elig asct either obtain adequ respons
schatz next-gener sequenc suggest complex heterogen pathogenesi peripher t-cell
approach newli diagnos relaps patient hematolog news
wilhelm et al first-lin therapi t-cell lymphoma extens long-term follow-up studi investig
role autolog stem cell transplant blood cancer journal
broccoli zinzani peripher t-cell lymphoma otherwis specifi blood doi
yi et al recent advanc understand manag t-cell lymphoma
induct therapi progress diseas median overal surviv mo r/r
patient candid asct month month respect salvag
chemotherapi margin improv outcom patient mo month
month fda recent approv drug treatment r/r
treatment r/r alcl approv base respons rate given neither
therapi improv os figur outlin mechan action efficaci safeti profil
sale approv r/r therapi
figur current approv therapi r/r
action
cd
poor median overal surviv r/r aml md emphas need new
acut myeloid leukemia aml diseas elderli aml common form acut leukemia
often develop consequ sever genet epigenet chang hematopoiet precursor cell
malign cell form clone prolifer uncontrol lack abil differenti overal surviv
patient aml decreas increas age median overal surviv mo newli diagnos elderli aml
month year overal surviv patient year age year rel surviv rate
mak et al surviv patient peripher t-cell lymphoma first relaps progress spectrum diseas
rare long-term survivor clin oncol
burnett et al comparison low-dos cytarabin hydroxyurea without all-tran retino acid
acut myeloid leukemia high-risk myelodysplast syndrom patient consid fit intens treatment cancer
elderli patient secondari aml often aris myelodysplast syndrom md
heterogen group malign hematopoiet stem cell disord defin dysplast ineffect blood cell
product propens transform acut leukemia allogen stem cell transplant
cur therapi md aileron current sponsor phase i/ib studi singl agent
combin cytarabin patient wild type r/r acut myeloid leukemia aml advanc
myelodysplast syndrom md mutat rare de novo aml mdmx overexpress
aml case
limit treatment option r/r aml md aml larg divid treatment phase remiss
induct post-remiss therapi
induct aml patient treat intens chemotherapi usual combin cytarabin
anthracyclin drug young adult older newli diagnos aml patient
experi complet remiss induct therapi
remiss therapi phase therapi involv chemotherapi target therapi stem cell
transplant autolog
relaps refractori set allogen hsct offer best cure patient r/r aml
chemotherapeut agent reduc malign cell act bridg allogen hsct serv
best option patient candid myeloabl hsct common regimen includ high-
dose cytarabin cytarabine-bas combin mitoxantron target agent
absenc definit standard md given chronic natur diseas advanc
age/frailti paient support care remain central compon md treatment recent
chemotherapeut hypomethyl agent emerg treatment option
support treatment includ antibiot infect aris result repeat red blood
cell platelet transfus patient md receiv repeat transfus high cost
treatment mean cost patient amount
intens therapi treatment includ hematopoiet growth factor azacitidin decitabin
high intens therapi usual includ intens combin chemotherapi allogen hsct
gener patient treat hematopoiet growth factor respond therapi howev
effect treatment patient refractori treatment patient year cumul incid
aml receiv hypomethyl agent lenalidomid variou
investig drug respect os patient receiv hypomethyl agent lenalidomid
variou investig drug mo md patient fail azacitidin
dombret claud updat current treatment adult acut myeloid leukemia blood pp
park et al outcom lower-risk patient myelodysplast syndrom without delet failur
month os alerion current sponsor phase i/ib r/r aml advanc
aml market
epidemiolog aileron therapeut target cancer indic either mdmx
overexpress function intact base initi phase proof concept clinic data compani
focus address patient relaps refractori peripher cell lymphoma r/r retain wild
type function aileron also target patient r/r acut myeloid leukemia aml r/r myelodysplast
syndrom md estim new case non-hodgkin lymphoma nhl diagnos us
peripher cell lymphoma repres newli diagnos rare
mutat harbor genet alter aml common
acut leukemia adult estim new case aml diagnos newli
diagnos case estim de novo case mutat rare de novo case aml
aris roughli affect roughli new case md diagnos year us
although mutat associ poor outcom md md case wild type
address market alerion initi target patient r/r r/r aml advanc
md wild type estim patient undergo induct therapi achiev
complet remiss cr patient achiev cr like candid autolog hsct
patient receiv autolog hsct achiev cr relaps rate patient
achiev one cr prior receiv autolog hsct attain cr prior transplant
use assumpt detail epidemiolog section estim potenti address market
alerion r/r figur
estim adult aml experi cr induct therapi remiss therapi
avail patient includ cytarabin hsct high-dos cytarabin standard contrast younger
patient high dose cytarabin toxic older individu dose attenu key administ post-
prbet et al outcom high-risk myelodysplast syndrom azacitidin treatment failur clin oncol
casulo et al t-cell lymphoma recent advanc character new opportun treatment jnci
schatz et al target mutat profil peripher t-cell lymphoma otherwis specifi highlight new
mechan heterogen pathogenesi leukemia
vasmatzi et al genome-wid analysi reveal recurr structur abnorm gene
peripher t-cell lymphoma blood
cavaj et al dual inhibit mdmx therapeut strategi leukemia tran
al-issa et al mutat outcom patient myelodysplast syndrom md blood
reemiss chemotherapi due gastrointestin central nervou system toxic although patient
treat post-remiss chemotherapi achiev cr remiss rate durabl diseas free surviv
month therefor assum patient relaps diseas
current pauciti treatment strategi patient md red blood cell transfus common
associ infect although patient respond hematopoiet growth factor increas blood
cell need therapi manag patient await allogen hsct figur outlin
total address market avail aileron aml md
figur address market aml md
address market
address market aml
rate ptcl
patient
incid wild
patient
wild type
rate de novo aml
de novo aml
incid wild type
de novo aml
patient wild type
address market md
incid wild type
md patient
wild type
popul
aml md
price approv therapi r/r current fda approv therapi market
r/r aileron demonstr efficaci indic believ compani would abl
command price similar approv product outlin
cycl treatment consist session total per cycl
beleodaq wac per packag packag per session cycl treatment consist
folotyn wac per packag packag per session cycl treatment consist
session total per cycl
shown sign efficaci r/r r/r aml advanc md
aileron previous complet phase dose escal all-com studi patient across
differ advanc solid tumor lymphoma well toler complet respons
februari compani initi expans cohort phase iia studi interim updat
expect aileron also sponsor phase ib studi r/r aml advanc md
show sign efficaci singl agent combin cytarabin md updat trial
expect figur present summari complet on-going clinic studi alrn-
figur summari clinic trial
liquid solid
merkel cell
r/r aml
monotherapi pt bone
safeti note pt death due tumor lysi
design open-label multi-cent dose-escal trial evalu patient advanc
liquid solid tumor cancer wild type studi assess safeti pk anti-cancer effect
drug patient random receiv one follow dose regimen
regimen qw patient receiv hour intraven infus day
regimen biw patient receiv hour intraven infus day
primari endpoint studi safeti toler achiev maximum toler dose
secondari endpoint includ evalu pharmacodynam marker immunogen efficaci measur
recist intern work group iwg
result studi report data enrol patient remain patient exclud due either
mutat allel and/or receiv less minimum therapeut dose deem
mg/kg/ dose final recommend phase ii dose mg/kg waterfal plot illustr efficaci alrn-
present figur diseas control rate dcr record complet respons cr
partial respons pr stabl diseas sd februari measur includ recist iwg
criteria observ patient anoth patient merkel cell carcinoma pr
observ colorect cancer liposarcoma term safeti dlt includ grade fatigu
mg/kg grade anemia hypotens neutropenia increas alkalin phosphatas mg/kg
clinic relev grade includ anemia neutropenia decreas white blood cell
decreas lymphocyt count grade data help support anti-cancer activ
select cancer suggest therapi well toler therapeut dose mg/kg
figur efficaci phase comer studi
on-going phase iia expans cohort studi
design open-label phase iia studi evalu patient r/r harbor wild
type patient receiv either mg/kg week week mg/kg alrn-
time week week primari endpoint studi overal respons rate orr secondari
endpoint includ pharmacokinet paramet recist iwg respons criteria
result studi complet initi accrual cohort receiv per week week
juli overal respons rate orr diseas control rate dcr evalu patient
cohort respect use lugano orr dcr use modifi
cheson et al criteria respect evalu figur highlight
radiograph scan patient achiev pr cycl therapi recruit three time per
week week cohort on-going updat expect
figur pr ptcl patient receiv
note studi report evid pseudo-progress late respons shown figur patient
meet diseas progress criteria patient remain therapi achiev partial respons pr
stabl diseas sd respons patient evalu use modifi cheson et al criteria
studi document earli diseas progress patient wild type tumor dose expans
cohort patient phase dose escal cohort tumor biopsi patient show
lesion still harbor wild type suggest either pseudo progress compani hypothesi adapt resist
mechan
figur pseudo-progress ptcl patient treat
on-going phase i/ib trial r/r aml advanc md
cheson et al recommend initi evalu stage respons assess hodgkin non-
cheson et al revis respons criteria malign lymphoma clin oncol
design open-label dose escal studi singl agent combin
cytarabin arac patient r/r aml advanc md wild type malign dose escal
portion studi patient aml receiv week week day time
week week start mg/kg follow one week drug holiday combin part studi
md patient receiv escal dose plu arac either week
compani also initi expans cohort phase ib studi md patient treat
mg/kg plu arac week week everi day primari endpoint
studi assess secondari endpoint includ immunogen efficaci use iwg criteria md
respons criteria
result aileron report data dose escal portion studi evalu monotherapi
show reduct bone marrow blast patient treat mg/kg week
week term safeti dlt observ cohort patient receiv mg/kg
compani recent gave updat dose escal cohort patient receiv mg/kg
next level per protocol aileron report death patient treat cohort due tumor lysi
syndrom tl result treatment report fda patient die year old
leukem blast per microlit baselin prior treatment accord compani leukem blast
significantli reduc infus week aileron hypothes fast onset
action result tl suggest strong activ drug patient enrol studi
monitor tl treat prophylact tl studi continu enrol patient
treat mg/kg per studi protocol expect updat trial
aileron complet dose escal portion combin studi patient treat mg/kg
plu arac week week everi day experienc marrow cr dlt
report studi continu enrol patient dose expans studi treat
mg/kg plu arac week week everi day updat portion
studi expect
competit landscap achiev high orr increas durabl
demonstr favor safeti profil success
current program advanc stage develop treatment r/r highlight
figur order competit program seek approv indic like build upon
respons rate seen approv therapi along toler safeti profil approv therapi
develop suffer hematolog toxic includ neutropenia thrombocytopenia
creat need safer therapi thu far demonstr toler safeti profil sign
clinic activ may also potenti improv upon current inhibitor develop
due activ mdmx final compani present favor preclin data
show potenti addit anti-tumor activ combin
inhibit distinct tumor type
figur drug advanc develop
class phase efficaci safeti
elev liver
mg bid
neutropenia
adcetri seattl genet seattl genet current assess adcetri brentuximab
vedotin phase trial conduct collabor takeda tyo compound antibody-
drug conjug made antibodi conjug monomethyl auristatin mmae
protease-cleav linker bind intern cell intracellular proteas cleav
mmae subsequ caus cell death linker system design stabl blood stream
releas mmae insid posit cell allow target cell death phase studi demonstr
adcetri combin full dose standard induct chemotherapi frontlin treatment system alcl
posit matur t/nk-cell lymphoma promis result phase ii trial led
initi phase trial patient untreat matur t-cell lymphoma
phase ii trial conduct open-label phase ii studi evalu singl agent adcetri relaps
refractori posit ptcl patient angioimmunoblast t-cell lymphoma aitl
peripher t-cell lymphoma otherwis specifi ptcl-no least prior system therapi
previou treatment adcetri enrol studi primari endpoint overal respons rate orr
secondari endpoint includ durat object respons dor progress free surviv
correl express figur display best clinic respons across studi
figur best clinic respons adcetri brentuximab vedotin ptcl-no
median durat respons patient month median month
appar correl respons express respect safeti data consist
known profil adcetri grade includ neutropenia hyperkalemia peripher sensori
neuropathi total patient experienc treatment-emerg grade includ pneumonia
sepsi lipas increas pulmonari edema treatment-rel seriou occur patient includ
grade pyrexia rash pneumonia one patient experienc grade acut respiratori distress
phase trial on-going random double-blind placebo-control phase studi
evalu adcetri plu cyclophosphamid doxorubicin prednison compar chop frontlin treatment
posit matur cell lymphoma primari endpoint per independ review secondari
endpoint includ cr orr top-line data studi expect fourth quarter
copiktra duvelisib verastem vstm copiktra duvelisib orally-avail inhibitor
gamma delta isoform phosphoinositid drug track design fda
evalu on-going phase ii studi patient r/r drug show sign activ
phase studi patient r/r orr treat patient includ
pr patient orr includ pr stabl diseas sd
term safeti grade ae includ increas alt ast rash pneumonia patient
grade alt ast elev grade pneumonia februari verastem initi multi-
center open-label phase ii primo studi evalu safeti efficaci duvelisib patient r/r
verastem report data phase studi evalu duvelisib plu remidepsin bortezomib patient r/r
tcl american societi hematolog meet studi open-label phase design
horwitz et al object respons relaps t-cell lymphoma single-ag brentuximab vedotin blood
evalu combin determin maximum toler dlt report grade
occur includ neutropenia term efficaci studi report orr
duvelisib plu remidepsin arm duvelisib plu bortezomib arm orr patient
ctcl
tipifarnib- tipifarnib farnesyl transferas inhibitor develop
variou oncolog indic farnesyl transferas requir activ ra cell membran
ra mutat roughli cancer difficult target mani mutat result perpetu
activ enzym result uncontrol prolifer malign cell tipifarnib prevent ra
recruit membran therebi preclud ra activ investigator-l phase ii studi evalu
tipifarnib relapsed/refractori lymphoma demonstr therapi well toler show efficaci
patient relapsed/refractori ptcl-no patient orr cr pr rate
compani initi open-label phase ii studi tipifarnib patient relapsed/refractori
patient receiv mg twice daili oral dose tipifarnib day follow interrupt treatment
treat anoth day primari endpoint studi orr key secondari endpoint
safeti durat compani report interim result june patient show
patient achiev pr addit patient achiev stabl diseas therapi particularli
effect patient aitl high level gene express suggest express could use
potenti biomark base activ zarnestra patient studi amend
includ expans cohort aitl common grade neutropenia anemia
thrombocytopenia among patient achiev pr patient aitl addit
patient sd
differenti approach reactiv show promis safeti efficaci
shown clinic activ solid liquid tumor alerion
demonstr respons aml md merkel cell carcinoma although orr r/r low
compar candid develop note data small number patient far
note thu far respons rate line seen approv hdac therapi alrn-
also demonstr respons patient r/r aml md phase ib studi report data
patient experienc reduct bone marrow blast md patient achiev marrow
plu arac combin arm howev note compani recent report death
patient dose escal portion on-going r/r aml md studi patient succumb tumor
lysi syndrom tl infus mg/kg time cours week recent
confer aileron manag suggest tl may brought rapid activ
moskowitz et al vitro parallel phase evid support safeti activ duvelisib
inhibitor combin romidepsin bortezomib relapsed/refractori t-cell lymphoma blood
witzig et al multi-institut phase studi farnesyltransferas inhibitor tipifarnib patient
relaps refractori lymphoma blood
drug sinc taken account measur monitor prophylact treat patient evid tl
look forward addit updat program
safeti profil may prove differenti compar approv therapi
first-in-human phase studi includ grade lymphocyt count decreas
grade case neutropenia thrombocytopenia promin approv candid therapi
develop respect compar favor neutropenia
thrombocytopenia approv agent
one hypothesi favor safeti profil may dual activ mdmx
stabil bone marrow mount evid suggest role regul prolifer
differenti apoptosi competit hematopoiet stem progenitor cell hspc hematopoiet
nich one studi found distinct role competit bone marrow particular
competit shown depend level stress dna damag competit bone-marrow
repopul experi prolifer graft cell radiat depend rel statu
surround marrow cell graft cell expand readili chimera competitor cell harbor wild type
heterozyg contrast less graft cell chimera null bone marrow cell therebi
highlight non-cel autonom role hspc whole studi suggest
level within marrow critic hspc competit regard possibl effect stabil
via dual inhibit mdmx result enhanc hspc prolifer
translat reduc neutropenia thrombocytopenia inde peripher blood analysi aml/md patient
treat show increas platelet neutrophil treatment correl
decreas shown figur
figur peripher blood analysi aml/md patient treat
note competit model may explain thrombocytopenia seen inhibitor posit
incomplet inhibit axi may result lower level function due potenti
upregul mdmx could lead decreas hspc prolifer subsequ thrombocytopenia
bondar medzhitov hematopoiet stem progenitor cell competit cell stem cell
inhibitor treat patient acknowledg hypothesi investig certainli
requir understand complet mechan importantli data addit patient treat alrn-
necessari better understand potenti safeti benefit
may differenti inhibitor clinic develop target
main focu oncolog given role variou malign target therapi direct
develop time begin discoveri nutlin cis-imidazolin
analog block interact main differ
inhibitor develop aileron drug inhibit mdmx remind mdmx
play critic role regul function effici inhibit protein requir
stabil subsequ activ chemic natur stapl peptid allow
dual inhibit model bind site critic interact
mdmx shown figur
acquisit resist mutat anti-canc drug major problem drug develop given
inhibit effect tumor type wild type plausibl long term treatment
antagonist may result select mutat mechan escap inde long cultur
cell nutlin result develop clone harbor mutat dna bind domain
abl elud inhibit theori possibl resist mutat could come
result mdmx inhibit howev date research clinic investig
seen evid resist mutat either preclin model clinic studi anoth potenti
mechan resist inhibit may adapt upregul mdmx posit
upregul mdmx may held bay given molecul abl inhibit
mdmx
may advantag inhibitor develop given complet stabil
may requir hspc prolifer surviv see safeti profil inhibitor present
figur also present phase clinic data inhibitor develop well indic current
pursu opportun compet base measur notabl safeti
profil note safeti data thu far small number patient term
competit within heme malign space roch idasanutlin inhibitor candid
evalu nhl howev numer inhibitor program address aml
advanc develop may sourc competit aileron program aml progress
compet program may posit readthrough aileron aml/md may support
mechanist rational regul axi
figur safeti efficaci inhibitor phase comer studi
neutropenia anc
tcp anc
thrombocytopenia
neutropenia
thrombocytopenia
current phase
evid
phase combin
cytarabine/ aml
phase i/ii
combin
phase i/ii comb
phase ib/iia comb
trametinib
phase ib comb
phase i/ aml
phase i/ aml
razak et al phase studi antagonist pegyl prodrug idasanutlin intraven
iv administr patient advanc solid tumor eu volum supplement page
yee et al abstract phase studi antagonist pegyl intraven prodrug
idasanutlin patient aml proceed aacr-nci-eortc intern confer molecular target
langenberg et al phase studi inhibitor patient advanc wild type
solid tumor multipl myeloma eur cancer
bauer et al phase studi inhibitor patient well/de-differenti liposarcoma
wd/dd lp solid tumor st lymphoma clin oncol suppl abstr
hyman chatterje de vo et al optim therapeut index inhibit result
dose- regimen-find phase studi pt wt advanc tumor present american
associ cancer research annual meet
stein chromik deangelo et al phase dose- regimen-find studi pt
advanc wt acut leukemia present american associ cancer research annual meet
ration combinatori approach may attract potenti partner opportun
play essenti role suppress tumor develop estim roughli human cancer
harbor mutat delet render non-funct remain cancer wild type
level tightli regul mdmx overexpress either factor lead inhibit
function across variou cancer given promin role tumor develop unforeseen
regul function may form part mechan action mani anti-canc drug therefor
possibl dual inhibit mdmx may complement cancer therapi
aileron current explor variou combinatori strategi potenti enhanc anti-tumor activ
select anti-canc agent preclin model breast cancer lymphoma colorect cancer rational
wild type major tumor type action target pursu
indic may intersect function compani shown preclin data breast cancer xenograft
model demonstr addit anti-prolif activ combin nyse
ibranc palbociclib shown figur rational particular combinatori approach may root
studi show loss function low express target gene associ resist
inhibit melanoma follow-on preclin studi show concomit inhibit
re-sensit melanoma cell suggest context reactiv inhibit
essenti anti-tumor
figur preclin result ibranc xenograft model breast cancer
razak et al phase studi antagonist pegyl prodrug idasanutlin intraven
iv administr patient advanc solid tumor eur cancer
martin et al abstract statu predict respons inhibit melanoma aacr
aileron also shown preclin data lymphoma colorect cancer demonstr addit anti-tumor activ
combin therapi shown figur mechanist rational
combin may found clinic data nsclc show patient express high level
low lower surviv rate compar patient low high level inde preclin
studi shown abl specif modul level colorect lung cancer cell
therefor conceiv may enhanc inhibit amplifi express tumor
type wild type function believ studi bode well aileron given increas appetit larg
pharma potenti combinatori therapeut approach inhibitor billion-dollar
therapeut class expect grow futur potenti partnership player space
mayb sourc capit aileron
figur preclin result therapi lymphoma colorect
cortez et al regul via natl cancer inst
aileron ip estat consist us foreign patent protect compani peptid
platform specif compani own exclus right patent pend patent applic
us compani also own exclus right least foreign patent anoth pend
foreign patent applic patent provid coverag variou aspect compani product candid
includ composit matter method use drug product formul diagnost method manufactur
method identifi activ compound patent expect expir variou date
elig term adjust extens respect alrn specif aileron
own exclus us patent least pend us patent applic anoth foreign
patent foreign patent applic cover composit matter formul manufactur process
manufactur precursor use thereof patent set expir aileron patent
portfolio also includ us patent pend us patent applic foreign patent foreign patent
applic licens compani presid fellow harvard colleg dana-farb cancer institut
dcfi expect expir
presid chief execut offic
prior ceo dr aivado serv svp cso aileron sinc septemb march
septemb dr aivado serv vice presid clinic develop pharmacovigil
taiho oncolog inc pharmaceut compani octob march dr aivado serv
senior medic director clinic develop group glaxosmithklin inc global pharmaceut
compani addit dr aivado instructor medicin beth israel deaco medic
center/harvard medic school prior industri experi dr aivado practic clinic medicin
germani ten year time award dr mildr scheel cancer research scholarship
award dr aivado german board-certifi physician intern medicin hematolog medic
oncolog receiv ph medic school univers dusseldorf
allen anni serv senior director biophys analyt technolog ailerion sinc
novemb previous director technolog develop schering-plough research
institut cambridg prior vice presid new neogenesi
pharmaceut acquir schere neogenesi dr anni co-develop
core drug discoveri platform affin selection-mass spectrometry-bas autom ligand identif
ali dr anni author sever patent public describ ali technolog
invent mani novel techniqu use ali studi protein-drug interact dr anni receiv
chemistri georgia institut technolog receiv ph chemistri harvard
senior vice presid chief offic
donald dougherti join aileron svp cfo june bring year financi leadership
focus biopharmaceut technolog sector serv presid sinc prior
mr dougherti held senior posit sever invest firm includ essex invest manag
princip portfolio manag lead biotechnolog analyst putnam
invest senior vice presid analyst specialti growth group
manag voyag over-the-counter emerg growth fund began invest
career endow manag research mr dougherti receiv william colleg
 new york univers cfa earli career
risk invest
consid invest aileron high-risk invest aileron develop stage compani
histori take treatment market current fda approv drug portfolio compani
program limit data date furthermor earli indic efficaci necessarili translat posit
late-stag result clinic trial result signific addit expens compani may requir addit
round dilut financ compani aileron may unabl obtain suffici capit fund plan
develop program regulatori risk associ develop drug aileron may
receiv fda approv candid despit signific time financi invest regulatori approv
market sell drug guarante drug penetr market sale may meet expect
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
